RxDoctor Payments Data

John Daliva, DO

Internal Medicine · Pomona, CANPI 1760836662

Payments from drug & device makers

$773in general payments, 2019–2025

Across 58 payments — averaging $13.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$232
  • Kestra Medical Technology Services, Inc.$192
  • Johnson & Johnson$136
  • Novartis$89
  • Smith+Nephew$33
  • AbbVie$21
  • plus $70 from 4 others

What the payments were for

  • Food & beverage$773100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$773 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$192,891
Medicare patients
368
Services billed
1,470

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$40,909
XifaxanRifaximin26$31,232
RexultiBrexpiprazole29$18,191
Sevelamer Carbonate23$10,216
Atrovent HfaIpratropium Bromide15$7,657
Levemir FlexpenInsulin Detemir21$3,666
Enoxaparin Sodium20$2,381
Atorvastatin Calcium150$1,979
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam11$1,937
CeftriaxoneCeftriaxone Sodium12$1,854
Lidocaine18$1,766
Humulin RInsulin Regular, Human33$1,609
Levetiracetam39$1,565
Midodrine Hcl30$1,494
Humulin N KwikpenInsulin Nph Human Isophane39$1,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$40,909113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Pomona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →